Abionyx Pharma H1 FY26 net loss widens to €4.81 million; revenue slips 8.96% to €1.93 million

• Abionyx Pharma posted a first-half net loss of €4.81 million, widening from €2.31 million a year earlier.
• Revenue slipped 8.96% to €1.93 million, attributed solely to IRIS Pharma’s ophthalmology CRO business.
• Operating loss narrowed to €2.27 million, while the financial result swung to a €2.54 million loss.
• Financial result included €1.6 million in expense from fair-value measurement of Fenja straight bonds and issuance costs.
• Cash and equivalents rose to €26.87 million; €6.2 million of a €8.7 million France 2030 sepsis award remains to be received.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abionyx Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260923812642) on September 23, 2026, and is solely responsible for the information contained therein.